文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga标记三聚体亲和体靶向PDGFRβ用于肝细胞癌PET显像的临床前评估

Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-31

本研究开发了靶向血小板衍生生长因子受体β(PDGFRβ)的新型三聚体亲和体ZTRI,并用68Ga标记为[68Ga]Ga-DOTA-ZTRI。通过生物信息学、免疫印迹、细胞结合、放射自显影和体内分布实验验证其特异性,并在二乙基亚硝胺诱导的原发性肝细胞癌大鼠及一例特发性肝细胞癌猕猴中进行PET/CT显像,结果显示该探针可清晰显示肿瘤病灶,每次扫描辐射吸收剂量为2.03E-02 mSv/MBq。

要点

  • PDGFRβ被验证为肝细胞癌新生血管的代表性生物标志物。
  • [68Ga]Ga-DOTA-ZTRI放射化学产率超过95%,在肝细胞癌肿瘤血管中呈特异性摄取。
  • 动物PET/CT显像成功显示原发肝细胞癌大鼠和猕猴的肿瘤病灶,每次扫描辐射吸收剂量为2.03E-02 mSv/MBq。

核心结论

  • 结果表明[68Ga]Ga-DOTA-ZTRI偶联物有望作为肝细胞癌早期诊断的PET示踪剂。

研究设计与样本

  • 临床前研究:对临床数据库进行生物信息学分析并对临床标本进行免疫印迹,以验证PDGFRβ作为肝细胞癌生物标志物的潜力。
  • 将三聚体亲和体ZTRI与DOTA-NHS-酯偶联并用68Ga标记,制备[68Ga]Ga-DOTA-ZTRI偶联物。
  • 通过剂量依赖性细胞结合、放射自显影和体内分布分析评估[68Ga]Ga-DOTA-ZTRI的免疫反应性和特异性摄取。
  • 对二乙基亚硝胺诱导的原发性肝细胞癌大鼠及一例特发性肝细胞癌猕猴进行[68Ga]Ga-DOTA-ZTRI PET/CT扫描,评估体内显像能力和辐射剂量。

主要发现

  • 过度表达的PDGFRβ被验证为肝细胞癌新生血管的代表性生物标志物。
  • [68Ga]Ga-DOTA-ZTRI的放射化学标记产率超过95%。
  • 体外实验通过放射自显影显示[68Ga]Ga-DOTA-ZTRI在肝细胞癌肿瘤血管中的特异性摄取。
  • 动物PET/CT显像中,[68Ga]Ga-DOTA-ZTRI成功显示原发性肝细胞癌大鼠和猕猴的肿瘤病灶。
  • 每次扫描的辐射吸收剂量为2.03E-02 mSv/MBq。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hepatocellular carcinoma (HCC) is a highly vascularized solid carcinoma and tumor vessel-targeted molecular imaging might be effective for early diagnosis of HCC. Herein, we developed a novel trimeric affibody (ZTRI) with highly specific binding to the platelet-derived growth factor receptor beta (PDGFRβ). The aim of this study is to evaluate the feasibility of 68Ga-radiolabeled ZTRI ([68Ga]Ga-DOTA-ZTRI) as PET tracer for diagnosis of HCC. METHODS: The bioinformatics analysis of clinical database and immunoblotting of clinical specimens were performed to validate the potential of PDGFRβ as HCC biomarker. The trimeric affibody ZTRI was conjugated with DOTA-NHS-ester and radiolabeled with 68Ga to produce [68Ga]Ga-DOTA-ZTRI conjugate. Immunoreactivity and specific uptake of [68Ga]Ga-DOTA-ZTRI were assessed by dose-dependent cell binding, autoradiography, and biodistribution analysis. [68Ga]Ga-DOTA-ZTRI PET/CT scanning of diethylnitrosamine (DEN)-induced primary HCC rats and a rare case of idiopathical HCC rhesus monkey was performed to evaluate the imaging capability and radiation dosimetry of [68Ga]Ga-DOTA-ZTRI in vivo. RESULTS: Excessive PDGFRβ was validated as a representative biomarker of HCC neovascularization. The radiolabeling of [68Ga]Ga-DOTA-ZTRI was achieved at more than 95% radiochemical yield. In vitro assays showed specific uptake of [68Ga]Ga-DOTA-ZTRI in HCC tumor vessels by autoradiography. Animal PET/CT imaging with [68Ga]Ga-DOTA-ZTRI successfully visualized the tumor lesions in primary HCC rats and rhesus monkey, and indicated radiation absorbed dose of 2.03E-02 mSv/MBq for each scanning. CONCLUSIONS: Our results demonstrated that [68Ga]Ga-DOTA-ZTRI conjugate could be applied as a promising PET tracer for early diagnosis of hepatocellular carcinoma.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cai H, Li Z, Shi Q, et al. Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37256321. doi:10.1007/s00259-023-06260-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。